利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

104 条记录 (耗时 0.041 秒)

    Nucleic acid encoding an interleukin-9 receptor variant
    81.
    发明授权
    Nucleic acid encoding an interleukin-9 receptor variant 失效
    编码白细胞介素-9受体变体的核酸

    公开(公告)号：US07208292B2

    公开(公告)日：2007-04-24

    申请号：US11371157

    申请日：2006-03-09

    申请人： Roy Clifford Levitt ,  Luigi Grasso ,  Nicholas C. Nicolaides ,  Kenneth J. Holroyd

    发明人： Roy Clifford Levitt ,  Luigi Grasso ,  Nicholas C. Nicolaides ,  Kenneth J. Holroyd

    IPC分类号： C12N5/10 ,  C12N15/12 ,  C12N15/63

    CPC分类号： C12Q1/6883 ,  A61K38/00 ,  C07K14/7155 ,  C12Q2600/156

    摘要： This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 171 The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and the use of such DNA molecules and expressed protein in the diagnosis and treatment of atopic asthma.

    摘要翻译： 本发明涉及用于发现基于哮喘相关因子2变体的特应性哮喘和相关病症的新治疗剂的诊断，治疗和方法。本发明的一个实施方案是AAF2的变体，其中密码子173缺失导致 来自成熟蛋白质前体的谷氨酰胺173。 该单个氨基酸缺失导致非功能性AAF2蛋白，因此该表型的存在应该与较少的特应性哮喘证据相关。 相应地，对哮喘，特应性表型的敏感性的缺乏的特征在于密码子171处的谷氨酰胺的丧失。本发明包括作为野生型序列的变体的分离的DNA分子以及由这样的DNA编码的蛋白质 DNA分子和表达蛋白在特应性哮喘的诊断和治疗中的应用。

    Nucleic acids encoding interleukin-9 receptor variants
    82.
    发明授权
    Nucleic acids encoding interleukin-9 receptor variants 有权
    编码白细胞介素-9受体变体的核酸

    公开(公告)号：US07056698B2

    公开(公告)日：2006-06-06

    申请号：US10320646

    申请日：2002-12-17

    申请人： Roy Clifford Levitt ,  Luigi Grasso ,  Nicholas C. Nicolaides ,  Kenneth J. Holroyd

    发明人： Roy Clifford Levitt ,  Luigi Grasso ,  Nicholas C. Nicolaides ,  Kenneth J. Holroyd

    IPC分类号： C12N5/10 ,  C12N15/12 ,  C12N15/63

    CPC分类号： C12Q1/6883 ,  A61K38/00 ,  C07K14/7155 ,  C12Q2600/156

    摘要： This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 173. The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and the use of such DNA molecules and expressed protein in the diagnosis and treatment of atopic asthma.

    摘要翻译： 本发明涉及用于发现基于哮喘相关因子2变体的特应性哮喘和相关病症的新治疗剂的诊断，治疗和方法。本发明的一个实施方案是AAF2的变体，其中密码子173缺失导致 来自成熟蛋白质前体的谷氨酰胺173。 该单个氨基酸缺失导致非功能性AAF2蛋白，因此该表型的存在应该与较少的特应性哮喘证据相关。 相应地，对哮喘，特应性表型的易感性的缺乏的特征在于173号密码子处的谷氨酰胺的丧失。本发明包括作为野生型序列的变体的分离的DNA分子以及由这种DNA编码的蛋白质的使用 这样的DNA分子和表达的蛋白质在特应性哮喘的诊断和治疗中。

    Methods for generating genetically altered antibody producing cell lines with improved antibody characteristics
    84.
    发明授权
    Methods for generating genetically altered antibody producing cell lines with improved antibody characteristics 有权
    用于产生具有改善的抗体特征的遗传改变的产生抗体的细胞系的方法

    公开(公告)号：US06808894B1

    公开(公告)日：2004-10-26

    申请号：US09707468

    申请日：2000-11-07

    申请人： Nicholas C. Nicolaides ,  Luigi Grasso ,  Philip M. Sass

    发明人： Nicholas C. Nicolaides ,  Luigi Grasso ,  Philip M. Sass

    IPC分类号： C12N1500

    CPC分类号： C07K16/00 ,  C07K2317/567

    摘要： Dominant negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. By introducing these genes into cells and transgenic animals, new cell lines and animal varieties with novel and useful properties can be prepared more efficiently than by relying on the natural rate of mutation. These methods are useful for generating genetic diversity within immunoglobulin genes directed against an antigen of interest to produce altered antibodies with enhanced biochemical activity. Moreover, these methods are useful for generating antibody-producing cells with increased level of antibody production.

    摘要翻译： 人类错配修复基因的主要阴性等位基因可用于产生超可变细胞和生物体。 通过将这些基因引入细胞和转基因动物，可以比通过依赖于突变的自然速率更有效地制备具有新颖和有用性质的新细胞系和动物品种。 这些方法可用于在针对感兴趣的抗原的免疫球蛋白基因内产生遗传多样性，以产生具有增强的生物化学活性的改变的抗体。 此外，这些方法可用于产生具有增加的抗体产生水平的产生抗体的细胞。

    Method for generating genetically altered antigens
    85.
    发明授权
    Method for generating genetically altered antigens 有权
    产生遗传改变抗原的方法

    公开(公告)号：US06737268B1

    公开(公告)日：2004-05-18

    申请号：US09712691

    申请日：2000-11-14

    申请人： Nicholas C. Nicolaides ,  Luigi Grasso ,  Philip M. Sass

    发明人： Nicholas C. Nicolaides ,  Luigi Grasso ,  Philip M. Sass

    IPC分类号： C12N1500

    CPC分类号： C12N15/1024

    摘要： Dominant negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. By introducing these genes into cells and transgenic animals, new cell lines and animal varieties with novel and useful properties can be prepared more efficiently than by relying on the natural rate of mutation. These methods are useful for generating genetic diversity within genes encoding for therapeutic antigens to produce altered polypeptides with enhanced antigenic and immunogenic activity. Moreover, these methods are useful for generating effective vaccines.

    摘要翻译： 人类错配修复基因的主要阴性等位基因可用于产生超可变细胞和生物体。 通过将这些基因引入细胞和转基因动物，可以比通过依赖于突变的自然速率更有效地制备具有新颖和有用性质的新细胞系和动物品种。 这些方法可用于在编码治疗性抗原的基因内产生遗传多样性，以产生具有增强的抗原性和免疫原性活性的改变的多肽。 此外，这些方法可用于产生有效的疫苗。

    Anti-Mesothelin Antibodies
    89.
    发明申请
    Anti-Mesothelin Antibodies 有权
    抗间皮素抗体

    公开(公告)号：US20120237509A1

    公开(公告)日：2012-09-20

    申请号：US13476656

    申请日：2012-05-21

    申请人： Wolfgang Ebel ,  Luigi Grasso ,  Nicholas C. Nicolaides ,  Philip M. Sass ,  Eric Routhier

    发明人： Wolfgang Ebel ,  Luigi Grasso ,  Nicholas C. Nicolaides ,  Philip M. Sass ,  Eric Routhier

    IPC分类号： A61K39/395 ,  C12N5/10 ,  C12N15/63 ,  C12N15/13 ,  A61P35/00

    CPC分类号： C07K16/28 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/3069 ,  C07K2317/56 ,  C07K2317/732 ,  C07K2317/77

    摘要： This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and become internalized by mesothelin-positive cells and also induce an immune effector activity such as antibody dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to mesothelin expressing cells as well as eliciting an immune-effector activity particularly on tumor cells and precursors. The invention is also related to cells expressing the monoclonal antibodies, polyclonal antibodies, antibody derivatives, such as human, humanized, and chimeric monoclonal antibodies, antibody fragments, mammalian cells expressing the monoclonal antibodies, derivatives and fragments, and methods of treating cancer using the antibodies, derivatives and fragments.

    摘要翻译： 本发明涉及单克隆和多克隆抗体的使用，其特异性结合并被间皮素阳性细胞内化，并且还诱导免疫效应子活性如抗体依赖性细胞毒性。 该抗体可用于特异性递送表达间皮素的药物学药剂，以及引发免疫效应物特异性对肿瘤细胞和前体的活性。 本发明还涉及表达单克隆抗体，多克隆抗体，抗体衍生物如人，人源化和嵌合单克隆抗体的细胞，抗体片段，表达单克隆抗体的哺乳动物细胞，衍生物和片段，以及使用 抗体，衍生物和片段。